Previous Page  21 / 25 Next Page
Information
Show Menu
Previous Page 21 / 25 Next Page
Page Background

Gastro Education 2018

Journal of Clinical Gastroenterology and Hepatology

ISSN: 2575-7733

Page 61

September 06-07, 2018

London, UK

14

th

International Conference on

Gastro Education

Introduction:

Novel immunotherapy strategies that may be

employedtorenderacancermoreimmunogenic,generateantigen-

speci c or nonspeci c immune activation, and/or manipulate the

tumor micro-environment. A number of immunotherapeutic trials

have been performed to evaluate the ef cacy of immunotherapy

for the treatment of HCC (hepatocellular carcinoma). Ambovex

is a botanical medicine derived from the plants belonging to the

family Ranunculaceae and having immune-modulating effect. In

this pilot study we used Ambovex as an immunotherapy trial for

treating Egyptian patients with unresectable HCC.

Patients & Methodology:

We included 148 patients with post-

HCV liver cirrhosis and HCC. Their HCC was diagnosed by

Ultrasound/CT and AFP >400 ngm and was un t for any of the

available treatment modalities. They were divided into 2 groups:

group 1 (88 patients) for treatment and group 2 (60 patients) as

a control group. After getting their informal consent, we gave for

group 1 Ambovex sublingual oral spray (20 buffs sublingual tid)

for 4 months. For group 2, sub- lingual glucose-saline sublingual

spray as a placebo. Both groups were followed up for one year.

Results:

There were no side effects apart from taste changes in

25% of patients in group I. In group I there was tumor regression

and signi cant decrease in AFP in 36 patients (40.9%), and 25

patients (28.4%) showed stable tumor size and AFP level and

27 patients (30.7%) showed disease progression. In group II, no

patients showed tumor stabilization. At one year follow-up 61

patients (69.3%) were still living in group I compared to only 21

patients (35%) in group II.

Conclusions:

From this pilot study, we could conclude that

Ambovex with its immune- modulating effect have initial

promising results in treating Egyptian patients with HCC. Further

controlled, randomized, multicenter studies are needed to con rm

these results.

hsalama888@yahoo.com

Ambovex oral sublingual spray as immuno-therapy trial for

HCC among Egyptian patients

Hosny Salama, Hassan Ahmed, Ismail, Elchagea, Abdel Rahman Zekri, Eman

Medhat, Midhead Lange, Mohamed Rabbat

and

Pravin Pumamiya

1

National Cancer Institute - Cairo University, Egypt

J Clin Gastroenterol Hepatol 2018, Volume 2

DOI: 10.21767/2575-7733-C2-006